加载中
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
收盘时
US$60.48
−US$1.58 · -2.55%
盘后
US$60.48
US$0.00 · 0.00%
10月12日 17:21 ET
盘中时间采用ET。市场数据可能有所延迟。
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
日内区间
当前US$60.48
52周区间
当前US$60.48
盘中时间采用ET。市场数据可能有所延迟。
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
日内区间
当前US$60.48
52周区间
当前US$60.48
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 1.71亿 USD | 9667.1万 USD | 6926.4万 USD | 3343.7万 USD | 2517万 USD |
| 销售、一般及管理费用 | 6538.2万 USD | 3304.9万 USD | 2186.1万 USD | 1403.8万 USD | 576.3万 USD |
| 营业费用 | 2.36亿 USD | 1.3亿 USD | 9112.5万 USD | 4747.5万 USD | 3093.3万 USD |
| 利息收入 | 2776.1万 USD | 2129.2万 USD | 1479.7万 USD | 70.9万 USD | 1.4万 USD |
| 利息支出 | 360.7万 USD | 57.2万 USD | — | — | 215.8万 USD |
| 折旧和摊销 | 28.1万 USD | 15.6万 USD | 10万 USD | 8.9万 USD | 3.2万 USD |
| 营业利润 | −2.36亿 USD | −1.3亿 USD | −9112.5万 USD | −4747.5万 USD | −3093.3万 USD |
| 净利润 | −2.12亿 USD | −1.09亿 USD | −7642.9万 USD | −4682.7万 USD | −3596.9万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$106
上涨空间 75.26%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2022年12月30日 | 1:10 | — | — |
已生效 2022年12月30日
1:10
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI7665.3万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM4584.83万0.06%787.4亿 USD0.19%US$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI4397.86万0.45%98.74亿 USD0.35%US$151.4-1.54%
Vanguard Extended Market ETFVXF2925.91万0.03%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO1623.49万0.12%139.17亿 USD0.24%US$353.71-0.86%
Dimensional - US Small Cap ETFDFAS1483.46万0.04%338.69亿 USD0.31%US$78.17-0.23%
iShares Biotechnology ETFIBB1366.23万0.13%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO1279.26万0.07%180亿 USD0.06%US$112.27-0.35%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
